RGDX Share Price

Open 0.12 Change Price %
High 0.12 1 Day 0.00 0.00
Low 0.11 1 Week 0.00 0.00
Close 0.12 1 Month 0.00 0.00
Volume 20100 1 Year 0.00 0.00
52 Week High 26.00
52 Week Low 0.00
RGDX Important Levels
Resistance 2 0.13
Resistance 1 0.13
Pivot 0.12
Support 1 0.11
Support 2 0.11
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.67 0.17%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OPXAW 0.01 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Response Genetics, Inc. (NASDAQ: RGDX)

RGDX Technical Analysis 5
As on 7th Aug 2015 RGDX Share Price closed @ 0.12 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.44 & Strong Sell for SHORT-TERM with Stoploss of 0.24 we also expect STOCK to react on Following IMPORTANT LEVELS.
RGDX Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
RGDX Other Details
Segment EQ
Market Capital 36730060.00
Sector Healthcare
Industry Medical Laboratories & Research
Offical website http://www.responsegenetics.com
RGDX Address
RGDX
1640 Marengo Street
6th Floor
Los Angeles, CA 90033
United States
Phone: 323-224-3900
Fax: 323-224-3096
Interactive Technical Analysis Chart Response Genetics, Inc. ( RGDX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Response Genetics, Inc.
RGDX Business Profile
Response Genetics, Inc. is a life sciences company engaged in the research and development of clinical diagnostic tests for cancer. The Company generates revenues primarily from sales of its ResponseDX diagnostic tests. It focuses on commercialization of its ResponseDX tests; developing additional diagnostic tests for assessing the risk of cancer recurrence, prediction of chemotherapy response and tumor classification in cancer patients, and expanding its testing services business by pursuing new technologies through collaborations and in-licensing to expand its business. It offers its ResponseDX test services nationwide. It offers tests for non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and gastric and gastroesophageal (GE), and melanoma cancer patients� tumor tissue specimens through its ResponseDX: Lung, ResponseDX: Colon and ResponseDX: Gastric test suites and ResponseDX: Melanoma. Effective August 26, 2013, Response Genetics Inc acquired Pathwork Diagnostics Inc.